🔗 Share this article

Given that the US undertakes historic changes to its vaccination guidelines, one figure has emerged somewhat surprisingly: Høeg, a US-based sports physician and public health researcher who rose to prominence by questioning coronavirus vaccinations throughout the global health crisis and has concentrated on alleged deaths after COVID-19 immunization in her recent position at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Program

Agency leaders had intended to reveal radical changes to the pediatric vaccine schedule recently, synchronizing the US with Denmark’s national calendar, sources say – a major change that would put the US out of step with a large portion of the international standard with no evidence for benefit. This reveal has been delayed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to address the audience at the meeting. She was newly appointed acting director of the FDA’s CDER, the fifth person to lead the center this calendar year.

A Shift at the Agency

The acting appointment could signify a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for halting specific pediatric vaccine recommendations in the US in order to be more in line with Denmark's approach, a country with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Qualifications

Høeg has no apparent experience in drug development, regulation or management, which has been standard for previous leaders of the biologics center. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in leading a large organization. She lacks background in industry regulation.”

Past directors of the center would “grasp legal statutes and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who ran the center have had.”

This division has an enormous portfolio at the agency, she stated.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There’s a biosimilars division, over-the-counter program and more, and all of those have to be looked after,” she noted. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant administrative component to the position, which oversees in excess of 5,000 personnel. “It’s a massive administrative position, if you perform it correctly,” she added.

Official Statement and Contentious Policies

When asked about concerns about Dr. Høeg's credentials and whether this appointment indicates more teamwork among agency officials on vaccines, a press secretary responded that the “inquiries rely on incorrect assumptions”.

“This background matches the functions of her position,” the representative explained, pointing to the period Høeg spent advising the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a contentious rapid medication authorization process that apparently troubled her predecessors. “By what process are these drugs being picked for this voucher program? Who makes the calls?” Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

In general, he stated, “the agency looks to be trending towards less stringent regulations of pharmaceuticals, except for shots.”

Established History on Vaccines

Regarding immunizations, Høeg has a more documented, if problematic, track record, some experts observe. She released a research paper using non-validated crowd-sourced reports to estimate the rate of myocarditis following Covid immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the current government encompassed altering regulations for novel immunizations and discontinuing “unnecessary” immunizations, she said after the election on a online show. At the agency, Høeg has allegedly floated the idea of excluding adolescent males from getting COVID-19 vaccinations.

“She’s an all-around dogmatist who starts off with her preconceived notions and works backwards to accommodate the data in a extremely disingenuous, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|